Real time response on dS_3: the Topological AdS Black Hole and the Bubble

We study real time correlators in strongly coupled N=4 supersymmetric Yang-Mills theory on dS_3 x S^1, with antiperiodic boundary conditions for fermions on the circle. When the circle radius is larger than a critical value, the dual geometry is the so-called "topological AdS_5 black hole". Applying the Son- Starinets recipe in this background we compute retarded glueball propagators which exhibit an infinite set of poles yielding the quasinormal frequencies of the topological black hole. The imaginary parts of the propagators exhibit thermal effects associated with the Gibbons-Hawking temperature due to the cosmological horizon of the de Sitter boundary. We also obtain R-current correlators and find that after accounting for a small subtlety, the Son-Starinets prescription yields the retarded Green's functions. The correlators do not display diffusive behaviour at late times. Below the critical value of the circle radius, the topological black hole decays to the AdS_5 "bubble of nothing". Using a high frequency WKB approximation, we show that glueball correlators in this phase exhibit poles on the real axis. The tunnelling from the black hole to the bubble is interpreted as a hadronization transition.Comment: 52 pages, 11 figures, typos corrected, references adde

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Accurate quantification of minimal residual disease during treatment of chronic myeloid leukaemia guides clinical decisions. The conventional minimal residual disease method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating leukemic cells and the BCR-ABL1 transcripts per cell. BCR-ABL1 genomic DNA only reflects leukemic cell number. We used both methods in parallel to determine the relative contribution of the leukemic cell number to molecular response. BCR-ABL1 DNA PCR and RQ-PCR were monitored up to 24 months in 516 paired samples from 59 newly-diagnosed patients treated with first-line imatinib in the TIDEL-II study. In the first 3 months of treatment BCR-ABL1 mRNA values declined more rapidly than DNA. By 6 months the two measures aligned closely. The expression of BCR-ABL1 mRNA was normalized to cell number to generate an expression ratio. The expression of e13a2 BCR-ABL1 was lower than that of e14a2 transcripts at multiple time points during treatment. BCR-ABL1 DNA was quantifiable in 48% of samples with undetectable BCR-ABL1 mRNA, resulting in minimal residual disease being quantifiable for an additional 5-18 months (median 12 months). These parallel studies show for the first time that the rapid decline in BCR-ABL1 mRNA over the first 3 months of treatment is due to a reduction in both cell number and transcript level per cell, whereas beyond 3 months falling levels of BCR-ABL1 mRNA are predominantly due to depletion of leukaemic cells.Ilaria S. Pagani, Phuong Dang, Ivar O. Kommers, Jarrad M. Goyne, Mario Nicola, Verity A. Saunders, Jodi Braley, Deborah L. White, David T. Yeung, Susan Branford, Timothy P. Hughes, and David M. Ros

Irrigating with polyacrylamide (PAM) - Nine years and a million acres of experience

Polyacrylamide (PAM) has been available commercially since 1995 for reducing irrigation-induced erosion and enhancing infiltration. The first series of practical field tests was conducted in 1991. PAM used for erosion control is a large water soluble (non-crosslinked) anionic molecule (12-15 megagrams per mole) containing < 0.05% acrylamide monomer. In controlled field studies PAM eliminated, on average, 94% (80-99% range) of sediment loss in field runoff from furrow irrigation, with a typical 15-50% relative infiltration increase on medium to fine textured soils compared to untreated controls. Similar but less dramatic results have been seen with sprinkler irrigation. Under some conditions infiltration is unchanged or can even be slightly reduced, e.g. in sandy soils or where PAM application rates are very high. Results are achieved with per irrigation field application rates of about 1 kg per hectare, for furrow irrigation, and 2 to 4 kg per hectare for sprinkler irrigation. Cost of PAM is $7 to$13 per kg. Seasonal application totals vary from 3 to 7 kg per hectare. Farmer field sediment control has been around 80% of test plot results. Substantial runoff reductions have been documented for nutrients, pesticides, microorganisms, BOD, and weed seed. No adverse effects have been seen for soil microbial populations. Crop yields have not been widely documented, though evidence exists for yield increases related to infiltration improvement. High effectiveness, low cost, and ease of application, compared to traditional conservation measures, has resulted in rapid technology acceptance in the US and internationally. PAM-use for runoff water quality protection is one of the most potent new irrigation environmental technologies in the market place. New uses in construction and dryland erosion control are being developed rapidly. This paper discusses new insights and understanding of PAM-use and potential for future development

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention

Early view: March 23, 2023The BCR::ABL1 gene fusion initiates chronic myeloid leukemia (CML), however evidence has accumulated from studies of highly selected cohorts that variants in other cancer-related genes are associated with treatment failure. Nevertheless, the true incidence and impact of additional genetic abnormalities (AGAs) at diagnosis of chronic phase (CP)-CML is unknown. We sought to determine whether AGAs at diagnosis in a consecutive imatinib-treated cohort of 210 patients enrolled in the TIDEL-II trial influenced outcome despite a highly proactive treatment intervention strategy. Survival outcomes including overall survival, progression-free survival, failure-free survival and BCR::ABL1 kinase domain mutation acquisition were evaluated. Molecular outcomes were measured at a central laboratory and included major molecular response (MMR, BCR::ABL1 ≤0.1%IS), MR4 (BCR::ABL1 ≤0.01%IS) and MR4.5 (BCR::ABL1 ≤0.0032%IS). AGAs included variants in known cancer genes and novel rearrangements involving the formation of the Philadelphia chromosome. Clinical outcomes and molecular response were assessed based on the genetic profile and other baseline factors. AGAs were identified in 31% of patients. Potentially pathogenic variants in cancer-related genes were detected in 16% of patients at diagnosis (including gene fusions and deletions) and structural rearrangements involving the Philadelphia chromosome (Ph-associated rearrangements), detected in 18%. Multivariable analysis demonstrated that the combined genetic abnormalities plus the ELTS clinical risk score were independent predictors of lower molecular response rates and higher treatment failure. Despite a highly proactive treatment intervention strategy, first-line imatinib-treated patients with AGAs had poorer response rates. This data provides evidence for the incorporation of genomically-based risk assessment for CML.Naranie Shanmuganathan, Carol Wadham, NurHezrin Shahrin, Jinghua Feng, Daniel Thomson, Paul Wang, Verity Saunders, Chung Hoow Kok, Rob M. King, Rosalie R. Kenyon, Ming Lin, Ilaria S. Pagani, David M. Ross, Agnes S.M. Yong, Andrew P. Grigg, Anthony K. Mills, Anthony P. Schwarer, Jodi Braley, Haley Altamura, David T. Yeung, Hamish S. Scott, Andreas W. Schreiber, Timothy P. Hughes and Susan Branfor

Towards evidence-based marketing: The case of childhood obesity

Contentious commodities such as tobacco, alcohol and fatty foods are bringing marketing under scrutiny from consumers and policymakers. Yet there is little agreement on whether marketing is harmful to society. Systematic review (SR), a methodology derived from clinical medicine, offers marketers a tool for providing resolution and allowing policymakers to proceed with greater confidence. This article describes how SR methods were applied for the first time to a marketing problem -- the effects of food promotion to children. The review withstood scrutiny and its findings were formally ratified by government bodies and policymakers, demonstrating that SR methods can transfer from clinical research to marketing

Mapping child growth failure across low- and middle-income countries

Childhood malnutrition is associated with high morbidity and mortality globally1. Undernourished children are more likely to experience cognitive, physical, and metabolic developmental impairments that can lead to later cardiovascular disease, reduced intellectual ability and school attainment, and reduced economic productivity in adulthood2. Child growth failure (CGF), expressed as stunting, wasting, and underweight in children under five years of age (0�59 months), is a specific subset of undernutrition characterized by insufficient height or weight against age-specific growth reference standards3�5. The prevalence of stunting, wasting, or underweight in children under five is the proportion of children with a height-for-age, weight-for-height, or weight-for-age z-score, respectively, that is more than two standard deviations below the World Health Organization�s median growth reference standards for a healthy population6. Subnational estimates of CGF report substantial heterogeneity within countries, but are available primarily at the first administrative level (for example, states or provinces)7; the uneven geographical distribution of CGF has motivated further calls for assessments that can match the local scale of many public health programmes8. Building from our previous work mapping CGF in Africa9, here we provide the first, to our knowledge, mapped high-spatial-resolution estimates of CGF indicators from 2000 to 2017 across 105 low- and middle-income countries (LMICs), where 99 of affected children live1, aggregated to policy-relevant first and second (for example, districts or counties) administrative-level units and national levels. Despite remarkable declines over the study period, many LMICs remain far from the ambitious World Health Organization Global Nutrition Targets to reduce stunting by 40 and wasting to less than 5 by 2025. Large disparities in prevalence and progress exist across and within countries; our maps identify high-prevalence areas even within nations otherwise succeeding in reducing overall CGF prevalence. By highlighting where the highest-need populations reside, these geospatial estimates can support policy-makers in planning interventions that are adapted locally and in efficiently directing resources towards reducing CGF and its health implications. © 2020, The Author(s)